Posted by Michael Wonder on 10 Jun 2023
A review of labeling based on patient reported outcome endpoints for new oncology drugs approved by the EMA (2017-2021)
9 June 2023 - A review of new oncology indications approved by the EMA for 2012-2016 showed that 33% of new drugs had labelling based on patient-reported outcomes.
Ari Gnanasakthy and colleagues reviewed labelling text based on patient reported outcomes endpoints for new oncology indications approved during 2017-2021.
